ABMC Phone: 800-227-1243

ABMC Reports Third Quarter 2015 Results

KINDERHOOK, N.Y. - November 16, 2015 - American Bio Medica Corporation (ABMC) today announced financial results for the three and nine months ended September 30, 2015.

Chief Executive Officer Melissa A. Waterhouse stated, "ABMC continues to be an extremely efficient manufacturing company, and we are pleased with our continued improvement in our bottom line results. We are still experiencing sales declines, however we have a number of potential new business relationships that we hope will have a positive impact on the top line in 2016 and beyond. In addition to these relationships, a new assay will be released in late 2015, and we are still taking steps to obtain marketing clearance from FDA. While our financial condition has dramatically improved over the last couple of years, we need to restore the top line so we can take additional steps needed to promote ABMC and increase shareholder value."

Financial Highlights

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our OralStat product, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2014, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

(financial tables follow)

Condensed Statements of Operations
For the three For the three For the nine For the nine
months ended months ended months ended months ended

September 30,

September 30,

September 30,

September 30,





Net sales $ 1,590,000 $ 1,750,000 $ 4,860,000 $ 5,604,000
Cost of goods sold 823,000 1,027,000 2,543,000 3,213,000
Gross profit 767,000 723,000 2,317,000 2,391,000
Operating expenses:
Research and development 45,000 92,000 125,000 183,000
Selling and marketing 291,000 280,000 899,000 839,000
General and administrative 388,000 475,000 1,332,000 1,408,000
Total operating expenses 724,000 847,000 2,356,000 2,430,000
Operating income / (loss) 43,000 (124,000) (39,000) (39,000)
Other income / (expense) (45,000) (87,000) (91,000) (212,000)
Loss before tax (2,000) (211,000) (130,000) (251,000)
Income tax (expense) / benefit 0 0 0 (1,000)
Net loss $ (2,000) $ (211,000) $ (130,000) $ (252,000)
Basic & diluted loss per common share $ (0.00) $ (0.01) $ (0.01) $ (0.01)

Weighted average shares outstanding –

basic and diluted





American Bio Medica Corporation
Condensed Balance Sheets
September 30, December 31,



Current Assets
Cash and cash equivalents $ 224,000 $ 352,000

Accounts receivable, net of allowance for doubtful accounts of
$46,000 at September 30, 2015 and $47,000 at December 31, 2014



Inventory, net of allowance of $387,000 at September 30, 2015 and
$334,000 at December 31, 2014



Current portion of deferred financing 0 43,000
Prepaid expenses and other current assets 80,000 85,000
Total current assets 2,954,000 3,016,000
Property, plant and equipment, net 923,000 983,000
Patents 69,000 65,000
Other assets 14,000 14,000
Deferred finance costs 256,000 0
Total assets $ 4,216,000 $ 4,078,000
Current liabilities
Accounts payable $ 429,000 $ 410,000
Accrued expenses and other current liabilities 211,000 192,000
Wages payable 287,000 264,000
Line of credit, net 931,000 979,000
Current portion of long-term debt, net 75,000 858,000
Total current liabilities 1,933,000 2,703,000
Other liabilities 68,000 68,000
Related party note 124,000 124,000
Long-term debt 934,000 213,000
Total liabilities 3,059,000 3,108,000
Stockholders’ Equity:
Common stock 260,000 236,000
Additional paid-in capital 20,649,000 20,356,000
Accumulated deficit (19,752,000) (19,622,000)
Total stockholders’ equity 1,157,000 970,000
Total liabilities and stockholders’ equity $ 4,216,000 $ 4,078,000

American Bio Medica Corporation
Melissa A. Waterhouse
Chief Executive Officer
(800) 227-1243, Ext 107